---
schema_version: "secwatch.filing_event.v1"
accession: "0001563665-23-000004"
form_type: "8-K"
ticker: "HRGN"
cik: "0001563665"
company_name: "Harvard Apparatus Regenerative Technology, Inc."
filed_at: "2023-01-12T23:59:59+00:00"
generated_at: "2026-06-20T15:59:46.925580+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Biostage CEO David Green made permanent; new agreement includes $300k salary, stock options

## Summary
- Interim tag removed; David Green named permanent CEO effective January 11, 2023.
- Annual base salary set at $300,000; cash incentive up to 100% of base salary.
- Initial stock option grants: $200k Black-Scholes value (monthly vesting over 12 months); fully vested option for $200k; LTI grant of 6% of outstanding shares (36-month vesting).
- Severance: $300,000 cash plus $200k Black-Scholes option if terminated without cause or for good reason.

## SEC filing metadata
- accession: 0001563665-23-000004
- form_type: 8-K
- ticker: HRGN
- cik: 0001563665
- company_name: Harvard Apparatus Regenerative Technology, Inc.
- filed_at: 2023-01-12T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 3.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563665/000156366523000004/0001563665-23-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563665/000156366523000004/tmb-20230111x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001563665-23-000004
- JSON: https://secwatch.observer/filing/0001563665-23-000004.json
- Plain text: https://secwatch.observer/filing/0001563665-23-000004.txt

## Key facts
- Executive change
  David Green changed role as Chief Executive Officer at Harvard Apparatus Regenerative Technology, Inc..
  - Action: removed Interim designation
  - Role: Chief Executive Officer
  source text: Effective as of January 11, 2023, Biostage, Inc. (the Company) entered into an Amended and Restated Employment Agreement (the Amended Agreement) with David Green, the Chief Executive Officer of the Company, to remove the Interim designation from his Chief Executive Officer title effective immediately
  evidence_url: https://www.sec.gov/Archives/edgar/data/1563665/000156366523000004/0001563665-23-000004-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.